Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients: Results from an experimental study

Neuropsychobiology

Volumn 47, Issue 4, 2003, Pages 212-218

  Kagerer, Sabine ^a   Winter, Catja ^a   Möller, Hans Jürgen ^a   Soyka, Michael ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atypical neuroleptics; Driving ability; Haloperidol; Psychomotor performance; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRIVING ABILITY; EVALUATION; FEMALE; HOSPITAL DISCHARGE; HUMAN; INTERMETHOD COMPARISON; MALE; MEDICAL ASSESSMENT; MENTAL DISEASE; NEUROPSYCHOLOGICAL TEST; PERFORMANCE; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; REACTION TIME; SCHIZOPHRENIA; VISUAL ACUITY; VISUOMOTOR COORDINATION;

ADULT; ANTIPSYCHOTIC AGENTS; AUTOMOBILE DRIVING; DOPAMINE ANTAGONISTS; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIA;

EID: 0038685914     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071217     Document Type: Article

References (23)

1. Kraepelin E: Dementia Praecox and Paraphrenia. Edinburgh, Livingstone, 1919.
2. Goldberg TE, Ragland JD, Torrey EF, et al: Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry 1990;47:1066-1072.
3. Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J: Does risperidone improve verbal working memory in treatment-resistent schizophrenia? Am J Psychiatry 1997;154:799-804.
4. Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H: Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996;6(suppl 2):S13-S20.
5. Ramaekers J, Louwerens J, Muntjewerff N, Milius H, DeBie A, Rosenzweig P, Patat A, O'Hanlon JF: Psychomotor, cognitive, extra-pyramidal, and affective function of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol 1999;19:209-221.
6. Harvey P, Keefe R: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001;158:176-184.
7. Lewrenz H: Begutachtungs-Leitlinien zur Kraftfahrereignung des Gemeinsamen Beirats für Verkehrsmedizin beim Bundesministerium für Verkehr, Bau und Wohnungswesen beim Bundesministerium für Gesundheit. Berichte der Bundesanstalt für Strassenwesen. Bergisch Gladbach, 2000, vol M115.
8. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-330.
9. Laux G: Zum Problem der Fahrtauglichkeit schizophrener Patienten unter Neuroleptikatherapie; in Möller HJ, Müller N (eds): Schizophrenie - moderne Konzepte zu Diagnostik, Pathogenese und Therapie. Wien, Springer, 1998.
10. Grabe HJ, Wolf T, Grätz S, Laux G: The influence of clozapine and typical neuroleptics on information processing of the central nervous system under clinical conditions in schizophrenic disorders: Implications for fitness to drive. Neuropsychobiology 1999;40:196-201.
11. Risser R, Schmidt L, Brandstätter C, Bukasa B, Wenninger U: Verkehrspsychologische Testverfahren und Kriterien des Fahrverhaltens. Wien, Verkehrspsychologisches Institut des Kuratoriums für Verkehrssicherheit, 1993.
12. Bukasa B, Wenninger U, Brandstätter C: Validierung verkehrspsychologischer Testverfahren. Kleine Fachbuchreihe des Kuratoriums für Verkehrssicherheit. Wien, Literas, 1990.
13. Soyka M, Dittert S, Schäfer M, Gartenmaier A, Laux G, Winter C, Möller HJ: Psychomotor performance under neuroleptic treatment in schizophrenia. A comparative study of haloperidol and risperidone. Z Neuropsychol 2001;12:49-53.
14. Palmer BW, Heaton RK, Gladsjo JA, Evans JD, Patterson TL, Golshan S, Jeste DV: Heterogeneity in functional status among older outpatients with schizophrenia: Employment history, living situation, and driving. Schizophr Res 2002;55:205-215.
15. Melzer HY, McGurk SR: The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-255.
16. Stip E, Lussier I: The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 1996;41(suppl 2):35-40.
17. Kern RS, Green MF, Marshall BD Jr, Wirshing WC, Wirshing D, Mc Gurk S. Marder SR, Mintz J: Risperidone vs haloperidol on reaction time, manual dexterity and motor learning in treatment-resistant schizophrenia patients. Biol Psychiatry 1998;44:726-732.
18. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY: Improvement in cognitive function and psychotic symptoms in treatment-refractory schizophrenic patients. Biol Psychiatry 1993;34:702-712.
19. Buchanan RW, Holstein C, Breier A: The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-725.
20. Purdon SE, Jones B, Stip E, Labelle A, Addington D, David S, Breier A, Tollefson G: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 2000;57:249-258.
21. Sax KW, Strakowski SM, Keck, PR: Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr Res 1998;33:151-155.
22. Classen W, Laux G: Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol or clozapine. Pharmacopsychiatry 1988;21:295-297.
23. Vollrath M, Krüger HP: Gefährdung der Verkehrssicherheit durch Alkohol, Drogen und Benzodiazepine - ein Überblick. Suchtmed 2002;4:175-183.